Literature DB >> 9466501

Removal of cytokine inducing substances by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma containing Staphylococcus aureus challenge.

B L Jaber1, T W Barrett, M Cendoroglo Neto, S Sundaram, A J King, B J Pereira.   

Abstract

Staphylococcus aureus (S. aureus) is frequently isolated from blood cultures in the hospital setting. The pathogenesis of S. aureus bacteremia probably replicates mechanisms implicated in gram negative bacterial infections. Cell wall components, such as peptidoglycans and lipoteichoic acids (LTA), can trigger cytokine production. Polymyxin-B (PMX-B) is a cationic peptide that binds endotoxin (ET) and inhibits its activity. Based on this principle, PMX-B was incorporated in polystyrene-derivative fibers, creating a hemoperfusion column (PMX-20R) that removes ET. The authors assessed whether S. aureus possesses PMX-B suppressible cytokine-inducing substances, and whether LTA, an anionic molecule, is one such substance. Heparinized blood was obtained from healthy volunteers, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque separation, and 10% human plasma prepared. PBMC were incubated with 1, 5, or 10 microg/ml of S. aureus LTA, with and without 10 microg/ml of PMX-B. Also, using PMX-20R, in vitro hemoperfusion (IVH) was performed with 10% human plasma containing a 1:1,000 dilution of S. aureus challenge at 100 ml/min for 2 hours at 37 degrees C, and plasma obtained before and after IVH was incubated with PBMC. After a 24 hour incubation at 37 degrees C, PBMC were subjected to three freeze-thaw cycles, and total TNFalpha was measured by radioimmunoassay. TNFalpha production by PBMC incubated with LTA was 164+/-4 pg, 324+/-54 pg, 657+/-55 pg, and 1143+/-215 pg in control, and LTA 1, 5, and 10 microg/ml, respectively. The addition of PMX-B resulted in a 40+/-12% (p = 0.02), 61+/-6% (p = 0.002), and 62+/-14% (p = 0.02) decrease in TNFalpha production, respectively. Before IVH, TNFalpha production by PBMC incubated with 10% plasma containing S. aureus challenge was 1275+/-70 pg. After 2 hours of IVH, the decrease in TNFalpha production was 20+/-4% (p = 0.002). In conclusion, S. aureus LTA induces TNFalpha production that is significantly suppressed by PMX-B. Consequently, S. aureus cytokine-inducing substances are removed during IVH with PMX-20R, and this may be due to stoichiometric binding of LTA to PMX-B.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466501     DOI: 10.1097/00002480-199801000-00011

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  6 in total

1.  Early recovery in hemodynamics after direct hemoperfusion with polymyxin B-immobilized fibers may predict mortality rate in patients with septic shock.

Authors:  Atsuko Kobayashi; Yasushi Iwasaki; Yuichi Kimura; Yoshiaki Kawagoe; Yoshihito Ujike
Journal:  J Anesth       Date:  2010-07-17       Impact factor: 2.078

2.  Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model.

Authors:  J E Wang; P F Jørgensen; M Almlöf; C Thiemermann; S J Foster; A O Aasen; R Solberg
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation.

Authors:  Hidehiko Kushi; Takahiro Miki; Kazuhiko Okamaoto; Jun Nakahara; Takeshi Saito; Katsuhisa Tanjoh
Journal:  Crit Care       Date:  2005-10-11       Impact factor: 9.097

Review 4.  Polymyxin B hemoperfusion: a mechanistic perspective.

Authors:  Claudio Ronco; David J Klein
Journal:  Crit Care       Date:  2014-06-09       Impact factor: 9.097

5.  Clinical effects of polymyxin B-immobilized fiber column direct hemoperfusion for severe bacterial meningitis: A series of 10 cases.

Authors:  Yoko Suzuki; Shingo Kawakami; Minako Yamada; Makoto Sohmiya; Ken Shibuya; Nobuya Maeda
Journal:  Clin Case Rep       Date:  2020-02-26

6.  Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

Authors:  Stephan Harm; Franz Gabor; Jens Hartmann
Journal:  Innate Immun       Date:  2016-03-17       Impact factor: 2.680

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.